| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Rat lens aldose reductase (RLAR): IC50 = 23.99 ± 2.30 μM [1]
Advanced glycation end products (AGEs) formation: IC50 > 1000 μM (no significant inhibition) [1] DPPH radical scavenging: IC50 = 94.60 ± 6.86 μM [1] |
|---|---|
| ln Vitro |
Calceolarioside B exhibited inhibitory activity against rat lens aldose reductase (RLAR) with an IC50 value of 23.99 ± 2.30 μM, as determined by spectrophotometric measurement of NADPH consumption at 340 nm using DL-glyceraldehyde as substrate. [1]
In the bovine serum albumin-methylglyoxal assay for advanced glycation end products (AGEs) formation, Calceolarioside B showed no significant inhibitory effect at tested concentrations, with an IC50 greater than 1000 μM, compared to the positive control aminoguanidine (IC50 = 820.44 μM). [1] The compound demonstrated DPPH radical scavenging activity with an IC50 value of 94.60 ± 6.86 μM, indicating moderate antioxidant capacity compared to L-ascorbic acid (IC50 = 54.39 μM). [1] |
| Enzyme Assay |
The inhibitory activity against rat lens aldose reductase (RLAR) was assayed spectrophotometrically. RLAR was prepared from lenses of Sprague-Dawley rats. Lenses weighing 250–280 g were removed and frozen at −70°C until use. Non-cataractous transparent lenses were pooled and homogenized in 0.1 M phosphate buffered saline (pH 6.2). The homogenate was centrifuged at 9600 × g for 20 minutes at 4°C, and the supernatant was collected as the crude RLAR enzyme source. The assay mixture (1.0 mL) contained equal units of the enzyme, 0.1 M sodium phosphate buffer (pH 6.2), 0.3 mM NADPH, with or without 10 mM DL-glyceraldehyde as substrate, and the test compound at various concentrations. The decrease in NADPH absorption at 340 nm was measured over a 4-minute period. The IC50 value (concentration causing 50% inhibition of enzyme activity) was calculated from the least squares regression line of logarithmic concentrations plotted against residual activity. [1]
The inhibition of advanced glycation end products (AGEs) formation was evaluated using a bovine serum albumin-methylglyoxal assay. Bovine serum albumin (50 mg/mL) was incubated with methylglyoxal (100 mM) in 0.1 M sodium phosphate buffer (pH 7.4) in the presence of various concentrations of Calceolarioside B (including a control) at 37°C for 24 hours. After incubation, the fluorescent intensity was measured at an excitation wavelength of 355 nm and an emission wavelength of 460 nm using a luminescence spectrometer. All reagents and samples were sterilized by filtration through 0.2 mm membrane filters. [1] The DPPH radical scavenging activity was determined using the stable free radical DPPH. A 0.32 mM solution of DPPH in methanol was prepared. Then, 180 μL of this solution was mixed with 30 μL of each sample (1.0 to 5.0 mg/mL in methanol). After 15 minutes of incubation in the dark, the decrease in absorbance was measured at 570 nm on a microplate reader. [1] |
| References | |
| Additional Infomation |
Calceolarioside B is a hydroxycinnamic acid that functions as a metabolite. It has been reported to be found in ash (Fraxinus insularis), plantain (Plantago depressa), and other organisms with relevant data.
Calceolarioside B (compound 4) was isolated from the ethyl acetate fraction of Stauntonia hexaphylla leaves (SHL) using Sephadex LH-20 column chromatography with MeOH-H2O (1:1, v/v) as the eluent, yielding 6.9 mg. Its chemical structure was identified by comparison of 1H and 13C NMR spectra and correlation NMR spectra (COSY, HMBC, HMQC) with previously reported data, as well as by MALDI-TOF MS (m/z 501.1398 [M+Na]+, 524.1296 [M+2Na]+). UV absorption maxima were at 218 nm and 327 nm. The compound is a phenolic glycoside (calceolarioside B). The study aimed to evaluate potential treatments for diabetic complications such as cataracts, as aldose reductase and AGEs are key targets in the polyol pathway and glycation process. Calceolarioside B showed moderate RLAR inhibition but no significant AGEs inhibition, suggesting its potential role may be more relevant to aldose reductase-related pathways. [1] |
| Molecular Formula |
C23H26O11
|
|---|---|
| Molecular Weight |
478.4459
|
| Exact Mass |
478.147
|
| CAS # |
105471-98-5
|
| PubChem CID |
5273567
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
799.8±60.0 °C at 760 mmHg
|
| Flash Point |
275.2±26.4 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.697
|
| LogP |
2.03
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
673
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC(=C(C=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)COC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O)O)O)O
|
| InChi Key |
LFKQVVDFNHDYNK-FOXCETOMSA-N
|
| InChi Code |
InChI=1S/C23H26O11/c24-14-4-1-12(9-16(14)26)3-6-19(28)33-11-18-20(29)21(30)22(31)23(34-18)32-8-7-13-2-5-15(25)17(27)10-13/h1-6,9-10,18,20-27,29-31H,7-8,11H2/b6-3+/t18-,20-,21+,22-,23-/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~522.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0901 mL | 10.4504 mL | 20.9008 mL | |
| 5 mM | 0.4180 mL | 2.0901 mL | 4.1802 mL | |
| 10 mM | 0.2090 mL | 1.0450 mL | 2.0901 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
